



SPARC/Sec/SE/2025-26/67

February 24, 2026

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

*Scrip Symbol:* SPARC

*Scrip Code:* 532872

**Reference- Extra-Ordinary General Meeting Outcome dated February 09, 2026**

**Subject- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Addendum to the Valuation Report**

Dear Sir/ Madam,

This is in continuation to our earlier intimation dated January 29, 2026 in respect of the Corrigendum to the EGM Notice.

Pursuant to the aforesaid EGM Notice, the Company has submitted an application for in-principle approval under the SEBI (ICDR) Regulations to the stock exchange.

Subsequently, National Stock Exchange of India Limited, vide their letter dated February 19, 2026 recommended further clarifications to the Valuation Report obtained from Mr. Jinesh Shah, Registered Valuer, pursuant to which the valuer has issued an Addendum to the Valuation Report.

The Addendum to the Valuation Report is available on the website of the Company at <https://sparc.life/statutorydisclosures/shareholders-meeting/>

This is for your information and record.

For **Sun Pharma Advanced Research Company Ltd.**

**Kajal Damania**  
**Company Secretary and Compliance Officer**  
Encl: As above

Date: February 24, 2026

To,  
The Board of Directors,  
Sun Pharma Advanced Research Company Limited  
Plot No. 5 & 6/1,  
Savli G.I.D.C. Estate,  
Savli - Vadodara Highway, Manjusar,  
Vadodara - 391775,  
Gujarat, India.

Dear Sir/Ma'am,

**Sub: Addendum to the Valuation Report**

This addendum is prepared to my Valuation Report dated January 1, 2026. In response to the query raised by the National Stock Exchange of India regarding the said Valuation Report, I wish to provide the following clarifications

1. Under the Scope of Information (page 7) : The words 'Unaudited financial statement for the period ended 30th September, 2025' should be read as 'Unaudited financial statements for the quarter ended 30th Sept 25, duly approved by the Board and subjected to limited review by the statutory auditors'
2. Income Approach – Detailed reason for not using DCF (page 17) : Detailed reasoning should be read as under:

The Income Approach, which includes the Price Earnings Capitalization Value (PECV) and Discounted Cash Flow (DCF) methods, relies fundamentally on the existence of stable, future economic benefits. As the Company has incurred persistent operational losses over the preceding financial years, there are no sustainable or maintainable earnings to capitalize.

With reference to using DCF analysis, the method requires projection of cash flows that the business is expected to generate and convert such cash flows to their present value by means of discounting. Such method requires availability of reliable projections derived through reasonable assumptions. I understand from the Company that ascertaining cash flows for Sun Pharma Advanced Research Company Limited ("SPARC") would be difficult due to the following reasons:

- Business model of the Company

SPARC is a clinical stage biopharmaceutical research and development company. Its operations are predominantly focused on:

- Pre-clinical research
- clinical trial execution across multiple phases, and
- development of novel pharmaceutical technologies.

These activities entail continuous investment outflows while revenue inflows, if any, arise only upon successful late stage development, out licensing or commercialization of product candidates.

- Scientific and development uncertainty

Drug development inherently carries a very low probability of success. In such scenario, projecting future licensing income, product revenues, or royalty streams would be contingent in nature and speculative, not meeting the reliability threshold required for applying the Income Approach

- Lack of Predictable or Recurring Revenue Streams

Company does not have an established or recurring revenue generating business model, as its operations remain predominantly focused on research and clinical development. Any income that may arise from R&D outcomes is inherently uncertain, irregular in timing, and contingent upon scientific progress, regulatory milestones, and external partnering decisions.

Further, the company has incurred consistent losses since incorporation, reflecting the absence of predictable or stable revenue inflows. These historical financial results clearly demonstrate that the company's revenue profile cannot be projected with reasonable certainty

In light of the foregoing, Management has not furnished any financial projections for the Company

DCF method estimates the present value of future economic benefits expected to be generated by the entity. It requires:

- reasonably predictable future revenues,
- identifiable cost structures,
- sufficient operating history to support assumptions
- Estimation of the quantum and timing of the cash flow

According to the information and explanations provided to me, I believe that the Company does not meet the above conditions.

Accordingly, valuation using the Income approach is not appropriate for valuing this company and has not been considered while valuing the company

I trust the above information addresses your queries satisfactorily

CA. Jinesh A. Shah  
Proprietor

IBBI Membership Number: IBBI/RV/06/2019/11939  
Date: February 24, 2026  
Place: Mumbai